Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 163Breast Neoplasms 123Lung Neoplasms 102Carcinoma, Non-Small-Cell Lung 84Glioblastoma 77Brain Neoplasms 75Neoplasm Metastasis 68Glioma 68Pancreatic Neoplasms 51Neoplasms 45Carcinoma, Renal Cell 45Multiple Myeloma 44Colorectal Neoplasms 44Squamous Cell Carcinoma of Head and Neck 39Lymphoma, Large B-Cell, Diffuse 39Carcinoma, Hepatocellular 36Melanoma 35Ovarian Neoplasms 34Lymphoma 34Urinary Bladder Neoplasms 33Astrocytoma 30Sarcoma 26Rectal Neoplasms 26Uterine Cervical Neoplasms 24Oropharyngeal Neoplasms 24Lymphoma, Follicular 24Central Nervous System Neoplasms 24Lymphoma, Non-Hodgkin 23Triple Negative Breast Neoplasms 22Gliosarcoma 22

Interventions

Specimen Handling 1Rituximab 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Classic Follicular Lymphoma × Magnetic Resonance Spectroscopy × Clear all
NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡